Floatz logo

Egfrbi-Armed Autologous Activated T Cells

Colon Carcinoma

Barbara Ann Karmanos Cancer InstituteCell therapyPhase 1Dormant
C
32/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
17/ 100
Competitive Position
89/ 100

Competitive context

28 Active assets in the Colon Carcinoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2B
Dabrafenib
National Cancer Institute (NCI)
Phase 2CCC
Crizotinib
National Cancer Institute (NCI)
Phase 2CCC
Gdc-0449
National Cancer Institute (NCI)
Phase 2CCC
Larotrectinib
National Cancer Institute (NCI)
Phase 2CCC

View all 35 →

Same molecule, other indications

Egfrbi-Armed Autologous Activated T Cells is also rated in:

colon carcinomaDormant
C
Indicative ·
32 / 100
View asset →
pancreatic neoplasmDormant
C
Indicative ·
32 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
32 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →